Results 11 to 20 of about 2,870,340 (221)
Effect of phosphodiesterase inhibitors in the bladder [PDF]
Asian Journal of Urology, 2015 Many aging men will experience lower urinary tract symptoms (LUTS). Phosphodiesterase type 5 (PDE5) inhibitors have shown promise in treating LUTS in these patients.
Bilal Chughtai +3 more
doaj +5 more sources
Phosphodiesterase inhibitors as adjunctive therapies for tuberculosis [PDF]
EBioMedicine, 2016 Mycobacterium tuberculosis (Mtb) is one of the most successful human pathogens, and a key mechanism in its virulence arsenal is its ability to influence host immune responses to its advantage. In recent years it has become clear that one such mechanism pivots on bacterial-derived, secreted small molecules that are released from the intracellular ...
Bintou Ahmadou Ahidjo, William R. Bishai
doaj +5 more sources
Phosphodiesterase Inhibitors [PDF]
International Cardiovascular Forum Journal, 2019 Phosphodiesterases (PDEs) comprise a superfamily with 11 subfamilies. Within these families, more than 40 isoforms are expressed. Phosphodiesterase-3 inhibitors (PDE3i) are used as inotrope/vasodilators for acute heart failure (HF), and PDE5i for ...
R. Plácido, M. Lainščak
semanticscholar +3 more sources
Selective Phosphodiesterase Inhibitors for Psoriasis: Focus on Apremilast. [PDF]
BioDrugs, 2015 Phosphodiesterase (PDE) 4 participates in regulating the inflammatory response by degrading cyclic adenosine 3′,5′-monophosphate (cAMP), a key second messenger.
Gooderham M, Papp K.
europepmc +2 more sources
Drug Design, Development and Therapy, 2016 Marilita M Moschos, Eirini Nitoda 1st Department of Ophthalmology, Medical School, National & Kapodistrian University of Athens, Athens, Greece Aim: The aim of this review was to summarize the ocular action of the most common phosphodiesterase (PDE)
Moschos MM, Nitoda E
doaj +2 more sources
Chemotherapeutic Efficacy of Phosphodiesterase Inhibitors in Chagasic Cardiomyopathy [PDF]
JACC: Basic to Translational Science, 2016 Molecular mechanisms of Trypanosoma cruzi (Tc)-induced Chagasic cardiomyopathy (CCM) are not well understood. The NO-cGMP-PKG1α pathway maintains cardiac homeostasis and inotropy and may be disturbed due to phosphodiesterase (PDE5)-mediated cGMP ...
Jian-jun Wen, PhD +3 more
doaj +2 more sources
The role of Phosphodiesterase-1 and its natural product inhibitors in Alzheimer’s disease: A review
Frontiers in Pharmacology, 2022 Phosphodiesterase-1 (PDE1) is a versatile enzyme that has surprisingly received considerable attention as a possible therapeutic target in Alzheimer’s disease (AD) because it maintains the homeostasis of 3ʹ,5ʹ-cyclic adenosine monophosphate (cAMP) and 3ʹ,
Nazir Ahmad +5 more
doaj +1 more source
Repurposing Phosphodiesterase-5 inhibitors as chemoadjuvants [PDF]
Frontiers in Pharmacology, 2013 Phosphodiesterase-5 (PDE5) inhibitors have shown a beneficial effect in a variety of clinical conditions, such as benign prostate hyperplasia, pulmonary arterial hypertension, female sexual arousal disorder, overactive bladder, and incontinence, Raynaud's disease, heart failure and stroke among others (Sandner et al., 2007).
Amit K. Tiwari, Zhe-Sheng eChen
doaj +4 more sources
Phosphodiesterase Inhibitors: Present and Future
Barcelona Respiratory Network Reviews, 2023 Phosphodiesterase (PDE) inhibitors act on specific phosphodiesterase enzymes (fundamentally 3, 4 and 5), which are characterized by their expression in different organs.
José L. Izquierdo-Alonso
doaj +1 more source
Annual Review of Pharmacology and Toxicology, 2022 Cyclic guanosine monophosphate (cGMP), an important intracellular second messenger, mediates cellular functional responses in all vital organs. Phosphodiesterase 5 (PDE5) is one of the 11 members of the cyclic nucleotide phosphodiesterase (PDE) family ...
Arun Samidurai +3 more
semanticscholar +1 more source